Related Experiment Video
Updated: Oct 18, 2025
Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
Published on: June 2, 2022
Agonist antibody discovery: Experimental, computational, and rational engineering approaches.
John S Schardt1, Harkamal S Jhajj2, Ryen L O'Meara3
1Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Discovering agonist antibodies, which activate cellular signaling for disease treatment, is challenging. Recent advances in high-throughput methods and molecular engineering are improving the discovery and optimization of these promising therapeutic antibodies.
Area of Science:
- Immunology
- Pharmacology
- Biotechnology
Background:
- Agonist antibodies represent a promising therapeutic class for various diseases by activating cellular signaling pathways.
- The identification and development of antibodies with specific agonist functions present a significant challenge in drug discovery.
- Despite hurdles, substantial progress has been made in developing agonist antibodies for diverse therapeutic targets.
Purpose of the Study:
- To review emerging high-throughput experimental and computational methods for discovering agonist antibodies.
- To discuss rational molecular engineering strategies for optimizing the agonist activity of antibodies.
- To provide an overview of current advancements in the field of therapeutic agonist antibodies.
Main Methods:
- High-throughput screening techniques for identifying potential agonist antibodies.
- Computational approaches, including in silico modeling and data analysis, for antibody discovery.
- Rational molecular engineering strategies focused on enhancing antibody-mediated cellular signaling.
Main Results:
- Identification of novel agonist antibodies against various therapeutic targets.
- Optimization of antibody binding and signaling properties through targeted engineering.
- Demonstration of improved therapeutic potential for engineered agonist antibodies.
Conclusions:
- Emerging high-throughput and computational methods accelerate agonist antibody discovery.
- Rational engineering significantly enhances the efficacy of therapeutic agonist antibodies.
- Advancements in agonist antibody development offer new therapeutic avenues for numerous pathologies.
